<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481194</url>
  </required_header>
  <id_info>
    <org_study_id>SDU/VS-HKU/CTC-2011-01</org_study_id>
    <nct_id>NCT01481194</nct_id>
  </id_info>
  <brief_title>ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <acronym>ACVDL</acronym>
  <official_title>An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the combination treatment&#xD;
      of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly&#xD;
      diagnosed multiple myeloma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">August 28, 2018</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 weeks after completion of 8 treatment cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>4 weeks after completion of 8 treatment cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very good partial response rate</measure>
    <time_frame>4 weeks after completion of 8 treatment cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ACVDL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2 IV on day 1 of a 21-day cycle</description>
    <arm_group_label>ACVDL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle</description>
    <arm_group_label>ACVDL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>15 mg orally on days 1-14 of a 21-day cycle</description>
    <arm_group_label>ACVDL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle</description>
    <arm_group_label>ACVDL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2 IV on day 1 of a 21-day cycle</description>
    <arm_group_label>ACVDL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥ 18 years at the time of signing informed consent.&#xD;
&#xD;
          2. Subject is diagnosed with symptomatic multiple myeloma based on the International&#xD;
             Myeloma Working Group Diagnostic Criteria (Kyle 2009):&#xD;
&#xD;
               -  Monoclonal plasma cells in the bone marrow ≥ 10% and/or presence of a&#xD;
                  biopsy-proven plasmacytoma.&#xD;
&#xD;
               -  Monoclonal protein present in the serum and/or urine. If no monoclonal protein is&#xD;
                  detected (non-secretory disease), then ≥ 30% monoclonal bone marrow plasma cells&#xD;
                  and/or a biopsy-proven plasmacytoma is required.&#xD;
&#xD;
               -  Myeloma-related organ dysfunction&#xD;
&#xD;
          3. The myeloma disease burden must be measurable with at least one of the following&#xD;
             criteria (Durie et al. 2006):&#xD;
&#xD;
               -  Serum M-protein ≥ 10 g/l&#xD;
&#xD;
               -  Urine M-protein ≥ 200 mg/24 h&#xD;
&#xD;
               -  Involved FLC ≥ 100 mg/l provided serum FLC ratio is abnormal&#xD;
&#xD;
               -  Bone marrow plasma cells &gt; 30%&#xD;
&#xD;
          4. Subject has a Karnofsky performance status of ≥ 60.&#xD;
&#xD;
          5. Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          6. Subject is willing and able to comply with the protocol as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior systemic therapy for multiple myeloma.&#xD;
&#xD;
          2. Other therapies such as biologic therapy and chemotherapy less than 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          3. Any prior treatment with doxorubicin or other anthracycline.&#xD;
&#xD;
          4. Concurrent or recent (less than 2 weeks prior to Screening) radiotherapy or surgery.&#xD;
&#xD;
          5. Prior glucocorticoid treatment of multiple myeloma exceeding dexamethasone 20mg/day&#xD;
             for a maximum of 7 days. Topical glucocorticosteroid therapy to treat non-malignant&#xD;
             comorbid disorders is permitted.&#xD;
&#xD;
          6. More than or equal to grade 2 peripheral neuropathy according to the NCI-CTC criteria&#xD;
             on clinical examination within 14 days before enrolment (Day 1 of Cycle 1).&#xD;
&#xD;
          7. Evidence of mucosal or internal bleeding and/or platelet counts &lt; 50 x 10^9/l.&#xD;
             Platelet transfusions may not be used to meet PLT eligibility criteria.&#xD;
&#xD;
          8. Absolute neutrophil count (ANC) &lt; 1 x 10^9/l. Growth factors may not be used to meet&#xD;
             ANC eligibility criteria.&#xD;
&#xD;
          9. Hemoglobin &lt; 5.0 mmol/l. The subject may be included after correction of the&#xD;
             hemoglobin level by transfusion or treatment with erythropoietin.&#xD;
&#xD;
         10. Alanine aminotransferase (ALAT) &gt; 2 x ULN.&#xD;
&#xD;
         11. Myocardial infarction within 6 months prior to enrolment or New York Heart Association&#xD;
             (NYHA) Class IV heart failure, uncontrolled angina, severe uncontrolled ventricular&#xD;
             arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction&#xD;
             system abnormalities. Prior to study entry, any ECG abnormality at screening has to be&#xD;
             documented by the investigator as not medically relevant.&#xD;
&#xD;
         12. Clinically relevant active infection or serious co-morbid medical conditions, such as&#xD;
             chronic obstructive or chronic restrictive pulmonary disease, and cirrhosis.&#xD;
&#xD;
         13. Any condition, including laboratory abnormalities, that in the opinion of the&#xD;
             Investigator places the subject at unacceptable risk if he/she were to participate in&#xD;
             the study.&#xD;
&#xD;
         14. Prior malignancy except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in situ cervical cancer, in situ breast cancer, or in situ prostate cancer for&#xD;
             which the subject has been disease-free for at least 3 years.&#xD;
&#xD;
         15. Female subject is pregnant or breast-feeding. The first serum pregnancy test to be&#xD;
             done within 10-14 days prior to the study treatment start and repeated serum pregnancy&#xD;
             test to be done within 24 hours prior to the start of study treatment.&#xD;
&#xD;
         16. Female subjects who are of childbearing potential (biologically capable of becoming&#xD;
             pregnant) or men with partners of childbearing potential, who are unwilling or unable&#xD;
             to use effective means of contraception. The means of contraception must be TWO&#xD;
             acceptable methods of birth control, one highly effective method (hormonal&#xD;
             contraceptives pills, injections or implants, tubal ligation, partner's vasectomy) and&#xD;
             one additional effective method (condom, diaphragm, cervical cap) AT THE SAME TIME, at&#xD;
             least 28 days before she or he starts ACVDL and for at least 28 days after the last&#xD;
             dose of ACVDL.&#xD;
&#xD;
         17. Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
         18. Uncontrolled diabetes mellitus at the discretion of the investigator.&#xD;
&#xD;
         19. Hypersensitivity and/or contraindication to any one of the Investigational Medicinal&#xD;
             Products (IMP), acyclovir or similar anti-viral drug.&#xD;
&#xD;
         20. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein (M-protein) and skin changes).&#xD;
&#xD;
         21. Known HIV infection.&#xD;
&#xD;
         22. Known active hepatitis B or C viral infection.&#xD;
&#xD;
         23. Known intolerance to steroid therapy.&#xD;
&#xD;
         24. Current or recent (within 30 days prior to Screening) treatment with another&#xD;
             investigational drug.&#xD;
&#xD;
         25. Unable to comply with the administration of the study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben Plesner, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

